Unique ID issued by UMIN | UMIN000048877 |
---|---|
Receipt number | R000055664 |
Scientific Title | Feasibility of Cognitive-Behavior Group Therapy for Depressive Disorders: Randomized Controlled Trial |
Date of disclosure of the study information | 2022/09/20 |
Last modified on | 2024/12/13 09:25:07 |
Feasibility of Cognitive-Behavior Group Therapy for Depressive Disorders: Randomized Controlled Trial
CoGrout Study
Feasibility of Cognitive-Behavior Group Therapy for Depressive Disorders: Randomized Controlled Trial
CoGrout Study
Japan |
Depressive Disorder
Psychiatry |
Others
NO
The purpose of this study is to evaluate the feasibility of Cognitive-Behavioral Group Therapy for depressive disorders.
Efficacy
Not applicable
Depressive symptom: PHQ-9(Patient Health Questionnaire
-Anxiety symptom: GAD-7(Generalized Anxiety Disorder)
-Self-Efficacy: GSES(General Self-Efficacy Scale)
-Personal Recovery: QPR-J(Japanese version of the Questionnaire about the Process of Recovery)
-Coping stress: CISS(Coping Inventory for Stressful Situation)
-QOL: WHO-QOL
-Disability: SDS(Sheehan Disability Scale)
-Others: Questionnaire on the use of CBT skills after participating in the group.
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
YES
YES
Institution is not considered as adjustment factor.
NO
Central registration
2
Treatment
Behavior,custom |
Cognitive-Behavioral Group Therapy
Treatment as usual
18 | years-old | <= |
70 | years-old | >= |
Male and Female
1. Subjects with DSM-V Depression Disorder
2. Subjects with CGIS(Clinical Global Impression)score is 3(mildly ill ), 4(Moderately ill), or 5(Markedly ill)
3. Subjects between the ages of 18 and 70 at the time of screening
4. Subjects ca obtain written consent
1. No alcohol or substance use disorder in 24 months prior to the screening.
2. No history of concurrent manic, or psychotic episodes.
3. No other primary Axis I Disorders in 6 months prior to the screening.
4. No comorbid antisocial personality disorder.
5. No serious suicidal ideation at screening.
6. Unlikely to attend more than 4 visits during the 8-week trial phase.
7. No treatment of CBT or CBGT within the last year prior to the screening.
8. No organic brain lesions or major cognitive deficits.
9. No severe or unstable medical illness at screening.
10. Other relevant reasons decided by the CogGrout study principal investigator.
40
1st name | Toshiaki |
Middle name | |
Last name | Kikuchi |
Keio University, School of Medicine
Department of Neuropsychiatry
160-8582
35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582
03-5363-3829
kikuchi.psychiatry@gmail.com
1st name | Miyuki |
Middle name | |
Last name | Tajima |
Keio University School of Medicine
Department of Neuropsychiatry
160-8582
35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582
03-5363-3829
taji0808@gmail.com
Keio University, School of Medicine
Grant in-Aid for Scientific Researchtific Research
Japanese Governmental office
Japan
1. Ichigaya Himorogi Clinic
2. Shinjuku Yoyogi Kokoro no Labo Clinic
3. Hamadayama Metal Clinic
Research Ethics Committee of Keio University, School of Medicine
35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582
03-3353-1211
med-rinri-jimu@adst.keio.ac.jp
NO
慶應義塾大学医学部/慶應義塾大学病院(東京都)
2022 | Year | 09 | Month | 20 | Day |
Unpublished
Completed
2022 | Year | 08 | Month | 29 | Day |
2023 | Year | 03 | Month | 28 | Day |
2022 | Year | 10 | Month | 01 | Day |
2025 | Year | 03 | Month | 31 | Day |
2022 | Year | 09 | Month | 07 | Day |
2024 | Year | 12 | Month | 13 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000055664